auristatin e

Auristatin E 通过阻断微管蛋白的聚合来抑制细胞分裂。它是一种细胞毒性微管蛋白修饰剂，具有强效和选择性抗肿瘤活性。它是一种 MMAE 类似物，是抗体-药物偶联物中的细胞毒素。

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound featuring Auristatin E, a potent cytotoxic tubulin modifier, connected through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

AminobenzenesulfonicauristatinE 是抗体偶联活性分子的一部分。AminobenzenesulfonicauristatinE 由细胞毒性微管蛋白修饰剂 AuristatinE 和 ADC linkerAminobenzenesulfonic 连接而成，具有抗肿瘤活性。

AminobenzenesulfonicauristatinE TFA，作为一种抗体偶联药物(Antibody-Drug Conjugate, ADC)的活性成分，该化合物通过Aminobenzenesulfonic和细胞毒性微管蛋白修饰剂AuristatinE的连接构建而成，展现出对肿瘤的抗性活性。

AminobenzenesulfonicauristatinE-d8 是 AminobenzenesulfonicauristatinE 的氘代替物,属于抗体药物偶联物(ADC)的成分之一.该化合物由细胞毒性微管蛋白修饰剂 AuristatinE 与 ADC linker Aminobenzenesulfonic 结合制成,赋予其抗肿瘤活性.

Monomethyl auristatin E (MMAE) 是海兔毒素 10 的合成衍生物，是一种抗有丝分裂剂，通过阻断微管蛋白的聚合来抑制细胞分裂，并且还具有抑制抗体-药物偶联物的活性。

Monomethyl auristatin E (GMP)是 Monomethyl auristatin E 的 GMP 级别试剂。Monomethyl auristatin E 是一种海兔毒素 10 的合成衍生物，是一种抗有丝分裂剂，通过阻断微管蛋白的聚合来抑制细胞分裂，并且还具有抑制抗体-药物偶联物的活性。

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) 是保护基团 (马来酰亚氨基己酰) 与 MMAE 共轭连接得到的化合物。它是微管蛋白抑制剂，可用于偶联抗体。

MMAU （β-D-Glucuronylmonomethylauristatin E）是一种有效载荷，这种糖苷类有效载荷在未结合的游离状态下相对稳定。通过溶酶体酶的作用将其转化为去糖基化状态后，会激活负载物的细胞毒性。

D8-MMAE (D8-Monomethyl auristatin E) is an effective mitotic inhibitor and tubulin inhibitor, deuterated MMAE.

m-PEG4-Br is a cleavable ADC linker used in the synthesis of an antibody-drug conjugate (ADC) for Trastuzumab. It is positioned distally from the monomethyl auristatin E (MMAE) payload, resulting in an ADC with modified hydrophilicity, antigen binding, and in vivo characteristics.

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.

DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor acting as a toxin payload in antibody-drug conjugates, is conjugated to a DBCO-(PEG)3-vc-PAB linker.

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound resulting from the conjugation of monomethyl auristatin E (MMAE), a potent tubulin inhibitor serving as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity.

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), comprising the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the cleavable linker SC-VC-PAB[1].

SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker comprising the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the SuO-Val-Cit-PAB peptide.

Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), comprising the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor), connected through the cleavable linker Azido-PEG4-Val-Cit-PAB-OH.

Disitamab vedotin (RC-48) 是一种新开发的靶向人表皮生长因子受体2（HER2） 的抗体-活性分子偶联物 (ADC) ，由 hertuzumab 偶联单甲基 auristatin E （MMAE） 通过可切割接头组成。Disitamab vedotin 在不同HER-2表达水平胃癌细胞中显示出抗肿瘤和抗增殖活性且抑制胃癌细胞中HER-2蛋白的表达。

Fmoc-MMAE, a protective group-conjugated variant of monomethyl auristatin E (MMAE), serves as a powerful inhibitor of tubulin. It finds application in the synthesis of antibody-drug conjugates (ADC).

Dov-Val-Dil-OH is a useful chemical intermediate for synthesis of auristatin-related compounds, such as Monomethyl auristatin E (MMAE), Auristatins are antimitotic agents which inhibits cell division by blocking the polymerisation of tubulin.

Zilovertamab vedotin (VLS-101) 是一种抗体-活性分子偶联物 (ADC), 主要由人源化单克隆抗体 zilovertamab 和单甲基 vedotin 组成的抗微管细胞毒素。该药物通过与肿瘤细胞表面的ROR1结合, 触发快速内化及向溶酶体的转运, 进而裂解释放单甲基 vedotin, 诱导细胞凋亡。适用于癌症的研究领域。

lifastuzumAb 是一种人源化的抗 NaPi2b 的 IgG1 类单克隆抗体，常与抗有丝分裂剂单甲基 auristatin E 偶联，通过阻断微管蛋白的聚合来抑制细胞分裂。

Polatuzumab vedotin是一种抗体药物偶联物，靶向CD79b。该化合物结合了人源化抗CD79b IgG1单克隆抗体和微管抑制剂monomethyl auristatin E (MMAE)，展现出针对大B细胞淋巴瘤（LBCL）的治疗潜力。